NCT06264609View on ClinicalTrials.gov

Precision Medicine Approach for Osteoporosis - Follow Up Study

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Osteoporosis
Interventions
DRUG

Alendronate

Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.

DRUG

Teriparatide

Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.

DRUG

Alendronate

Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.

Trial Locations (1)

40536

University of Kentucky, Lexington

All Listed Sponsors
lead

Paul F Netzel

OTHER